Cstone Pharmaceuticals Co. Ltd., of Suzhou, China, submitted an application for clinical trial approval to Human Research Ethics Committees of Linear Clinical Research Center in Australia for CS3006, a small-molecule inhibitor of mitogen-activated protein kinase.